ENLIVEN THERAPEUTICS, INC. Cash and Restricted Cash
ENLIVEN THERAPEUTICS, INC. (ELVN) had Cash and Restricted Cash of $135.50 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $135.50M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $132.18M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $98.90M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $101.73M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $135.50M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $132.18M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $98.90M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $101.73M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $119.44M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $101.70M 10-Q · filed 2026-05-07 | |
| 2024-12-31 | $124.17M 10-Q · filed 2026-08-05 | |
| 2024-09-30 | $100.67M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $96.92M 10-Q · filed 2025-08-13 | |
| 2024-03-31 | $149.22M 10-Q · filed 2025-05-14 | |
| 2023-12-31 | $100.19M 10-K · filed 2026-03-03 | |
| 2023-09-30 | $73.90M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $125.77M 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $292.16M 10-Q · filed 2024-05-14 | |
| 2022-12-31 | $75.59M 10-K · filed 2025-03-13 | $88.20M 10-K · filed 2023-02-10 |
| 2022-09-30 | $86.21M 10-Q · filed 2023-11-09 | $49.49M 10-Q · filed 2022-10-25 |
| 2022-06-30 | $92.51M 10-Q · filed 2023-08-10 | $30.61M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $99.93M 10-Q · filed 2023-05-11 | $36.66M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $110.08M 10-K · filed 2024-03-14 | $48.48M 10-K · filed 2022-03-15 |
| 2021-09-30 | $75.47M 10-Q · filed 2022-10-25 | |
| 2021-06-30 | $48.21M 10-Q · filed 2022-08-03 | |
| 2021-03-31 | $53.53M 10-Q · filed 2022-05-06 | |
| 2020-12-31 | $130.42M 8-K · filed 2023-06-23 | $47.79M 10-K · filed 2021-03-05 |
| 2020-09-30 | $34.25M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $54.74M 10-Q · filed 2021-08-06 | |
| 2020-03-31 | $86.81M 10-Q · filed 2021-05-11 | |
| 2019-12-31 | $5.02M 10-K · filed 2022-03-15 | |
| 2019-09-30 | $17.17M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $45.32M 10-Q · filed 2020-08-14 | |
| 2019-03-31 | $48.90M 10-Q · filed 2020-05-07 | |
| 2018-12-31 | $7.38M 10-K · filed 2021-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |